Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial

Authors: Tobias Nordström, Andrea Discacciati, Martin Bergman, Mark Clements, Markus Aly, Magnus Annerstedt, Axel Glaessgen, Stefan Carlsson, Fredrik Jäderling, Martin Eklund, Henrik Grönberg, Carin Cavalli-Björkman, Astrid Björklund, Britt-Marie Hune, Mark Clements, Shuang Hao, Andrea Discacciati, Henrik Grönberg, Martin Eklund, Tobias Nordström, Stefan Carlsson, Markus Aly, Mats Walldén, Ola Steinberg, Karl Andersson, Fredrik Jäderling, Fredrik Wimmercranz, Edward Meurling, Axel Gleassgen, Nada Majeed, Rihab Awadelkarim, Ing‐Marie Fyhr, D. Sandstrom, Linda Waage, Otabek Imamov, Rafael Lantz, Andreas Thorstensson, Carl Stiernstedt, Dushaid Wande, Gunnar Trygg, Harald Söderbäck, Jerzy Michajłowski, Lars Leykamm, Nils-Erik Svedberg, Lars Leykamm, Raimundas Sabockis, Sirvan Akrawi, Martin Bergman, Magnus Annerstedt, Martin Bergman, Magnus Annerstedt - The Lancet 2021 cited by 195